Study to Evaluate the Effects of AZD3427 in Patients With Heart Failure

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 23, 2021

Primary Completion Date

August 2, 2022

Study Completion Date

August 2, 2022

Conditions
Heart Failure
Interventions
DRUG

AZD3427

Patients will receive 5 IA infusions of AZD3427 into the brachial artery. The IA infusions of AZD3427 will be administered via a syringe pump, using a polypropylene syringe containing 0.9% (w/v) saline and delivered through an administration set comprising a syringe, extension tubing (PVC), and a 0.2- or 0.22-μm PVDF syringe filter.

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY